<DOC>
	<DOCNO>NCT02745860</DOCNO>
	<brief_summary>Clinical study healthy adult subject compare adult tablet selexipag tablet develop child .</brief_summary>
	<brief_title>Comparison Two Dose Strengths Selexipag Healthy Adults</brief_title>
	<detailed_description>Healthy male adult receive single dose selexipag ( 200 µg ) use different tablet strength ( 4 film-coated pediatric tablet 50 µg versus one film-coated tablet 200 µg selexipag ) two study period . There washout 7-9 day two study treatment administration .</detailed_description>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Key inclusion Criteria : Male subject age 18 45 year ( inclusive ) screening Signed informed consent form Body mass index ( BMI ) 18.0 28.0 kg/m2 ( inclusive ) screen Healthy basis physical examination , cardiovascular assessment laboratory test Key exclusion Criteria : Any contraindication study treatment History clinical evidence disease medical / surgical condition treatment , may put subject risk participation study may interfere absorption , distribution , metabolism excretion study treatment Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>selexipag</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>